Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after
antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability …

Peptide‒drug conjugates (PDCs) are drug delivery systems consisting of a drug covalently
coupled to a multifunctional peptide via a cleavable linker. As an emerging prodrug strategy …

Over the last couple of decades, stimuli-responsive supramolecular gels comprising
synthetic short peptides as building blocks have been explored for various biological and …

Peptide-drug conjugates (PDCs) are the new hope for targeted therapy after antibody-drug
conjugates (ADCs). Compared with ADCs, the core advantages of PDCs are enhanced …

The past decades witnessed an increasing interest in peptides as clinical therapeutics.
Rightfully considered as a potential alternative for small molecule therapy, these remarkable …

Carrier-free delivery of therapeutically relevant small molecules and functional
oligonucleotides is extremely challenging and is one of the major hurdles in cancer therapy …

Drug-based hyperbranched polymers have attracted broad interest from scientists due to
their attractive and distinctive characteristics in cancer chemotherapy. However, the only use …

Hypoxia is a common symptom of many serious disorders, including cancer, ischemic
strokes, and rheumatoid arthritis. It is a natural physiologic barrier seen in the …

The biological function of scaffolds plays an important role in the promotion of tissue
formation. Especially, biodegradation and bioactivity are important functions for cell …

Synthetic peptides, peptides built via chemical methodology or through recombinant
technology, have been designed for use in therapeutics. Current chemical methods to create …